KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

BioNTech SE (BNTX) Research & Development: 2018-2025

Historic Research & Development for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to -$660.3 million.

  • BioNTech SE's Research & Development fell 9.25% to -$660.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 billion, marking a year-over-year decrease of 1.51%. This contributed to the annual value of $2.4 billion for FY2024, which is 25.56% up from last year.
  • BioNTech SE's Research & Development amounted to -$660.3 million in Q3 2025, which was down 14.58% from -$576.3 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Research & Development ranged from a high of -$242.2 million in Q2 2021 and a low of -$660.3 million during Q3 2025.
  • Over the past 3 years, BioNTech SE's median Research & Development value was -$576.3 million (recorded in 2025), while the average stood at -$559.7 million.
  • In the last 5 years, BioNTech SE's Research & Development plummeted by 101,360,678.81% in 2021 and then increased by 8.46% in 2025.
  • Quarterly analysis of 5 years shows BioNTech SE's Research & Development stood at -$310.6 million in 2021, then plummeted by 67.46% to -$520.1 million in 2022, then declined by 19.53% to -$621.7 million in 2023, then decreased by 5.16% to -$653.8 million in 2024, then declined by 9.25% to -$660.3 million in 2025.
  • Its Research & Development was -$660.3 million in Q3 2025, compared to -$576.3 million in Q2 2025 and -$552.9 million in Q1 2025.